Seet Raymond C S, Zhang Yi, Wijdicks Eelco F, Rabinstein Alejandro A
Department of Neurology, Mayo Clinic, W8B, 200 First St SW, Rochester, MN 55905, USA.
Arch Neurol. 2011 Nov;68(11):1454-8. doi: 10.1001/archneurol.2011.248.
It is unclear whether stroke patients with atrial fibrillation (AF) are prone to adverse outcomes following treatment with intravenous recombinant tissue plasminogen activator, and whether the burden of AF affects these outcomes.
To investigate the contribution of AF (whether it be a first-detected episode of AF or chronic AF) to stroke outcomes in patients treated with intravenous recombinant tissue plasminogen activator.
Retrospective study.
Academic hospital. Patients Consecutive patients with acute ischemic stroke who received intravenous recombinant tissue plasminogen activator within 3 hours from symptom onset were included. Vascular risk factors, stroke characteristics, and outcome measures were compared between patients with and without AF.
Symptomatic intracranial hemorrhage and poor functional recovery (modified Rankin Scale score of >2).
Of the 214 patients who were studied (mean [SD] age, 74 [14] years, with 50% of patients being men), 21 had a first-detected episode of AF, and 55 had chronic AF. The incidence of symptomatic intracranial hemorrhage was significantly higher in patients with chronic AF than in patients without AF (16% vs 5%), and the incidence of poor functional recovery was significantly higher in patients with chronic AF than in patients without AF (62% vs 44%). The increase in risk of symptomatic intracranial hemorrhage (but not in poor functional recovery) among patients with chronic AF remained significant after adjusting for age and baseline National Institutes of Health Stroke Scale score (odds ratio, 2.95 [95% CI, 1.12-9.30]). Patients with chronic AF who developed a symptomatic intracranial hemorrhage had a longer duration of AF than those who did not (59 vs 23 months), and patients with chronic AF who had a poor functional recovery had a longer duration of AF than those who did not (36 vs 16 months) (P < .05). By contrast, there were no differences in outcomes between patients with a first-detected episode of AF and those without AF, and between patients with paroxysmal AF and those with persistent or permanent AF.
Patients with chronic AF have worse stroke outcomes than do patients without AF, and the risk for worse outcomes was greater in patients with a longer duration of AF.
尚不清楚心房颤动(AF)的卒中患者在接受静脉注射重组组织型纤溶酶原激活剂治疗后是否易于出现不良结局,以及AF的负担是否会影响这些结局。
探讨AF(无论是首次检测到的AF发作还是慢性AF)对接受静脉注射重组组织型纤溶酶原激活剂治疗的患者卒中结局的影响。
回顾性研究。
学术医院。患者 纳入症状发作3小时内接受静脉注射重组组织型纤溶酶原激活剂的急性缺血性卒中连续患者。比较有AF和无AF患者的血管危险因素、卒中特征和结局指标。
有症状性颅内出血和功能恢复不良(改良Rankin量表评分>2)。
在研究的214例患者(平均[标准差]年龄,74[14]岁,50%为男性)中,21例为首次检测到的AF发作,55例为慢性AF。慢性AF患者有症状性颅内出血的发生率显著高于无AF患者(16%对5%),慢性AF患者功能恢复不良的发生率显著高于无AF患者(62%对44%)。在调整年龄和基线美国国立卫生研究院卒中量表评分后,慢性AF患者有症状性颅内出血风险的增加(但功能恢复不良风险未增加)仍然显著(比值比,2.95[95%CI,1.12-9.30])。发生有症状性颅内出血的慢性AF患者的AF持续时间长于未发生者(59对23个月),功能恢复不良的慢性AF患者的AF持续时间长于未发生者(36对16个月)(P<.05)。相比之下,首次检测到AF发作的患者与无AF患者之间,阵发性AF患者与持续性或永久性AF患者之间的结局无差异。
慢性AF患者的卒中结局比无AF患者更差,且AF持续时间较长的患者结局更差的风险更大。